| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-00 |
| filingDate |
2006-06-29^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-01-18^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ef90d22c9a016b4b0bcd19fc850276a |
| publicationDate |
2011-01-18^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7872020-B2 |
| titleOfInvention |
TGF-β inhibitors |
| abstract |
The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro -4H-pyrrolo[1,2-b]pyrazole monohydrate. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110582497-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018165979-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10995083-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11111248-B2 |
| priorityDate |
2005-07-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |